A subcutaneous answer to PD-1’s patent problem
PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.
PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.
Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently.
EQRX had once hoped to disrupt cosy US cancer drug pricing arrangements, but when that model failed the group found that cash was its best asset.
However, endometrial cancer remains a small use, and Jemperli has other ways to make a bigger splash.
Excluding BRCA-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer, Astra’s Duo-O suggests.